Phase II trial of proton therapy versus photon IMRT for GBM: Secondary analysis comparison of progression-free survival between RANO versus clinical assessment

Karine A. Al Feghali, James W. Randall, Diane D. Liu, Jeffrey S. Wefel, Paul D. Brown, David R. Grosshans, Sarah A. McAvoy, Maguy A. Farhat, Jing Li, Susan L. McGovern, Mary F. McAleer, Amol J. Ghia, Arnold C. Paulino, Erik P. Sulman, Marta Penas-Prado, Jihong Wang, John De Groot, Amy B. Heimberger, Terri S. Armstrong, Mark R. GilbertAnita Mahajan, Nandita Guha-Thakurta, Caroline Chung*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background. This secondary image analysis of a randomized trial of proton radiotherapy (PT) versus photon intensity-modulated radiotherapy (IMRT) compares tumor progression based on clinical radiological assessment versus Response Assessment in Neuro-Oncology (RANO). Methods. Eligible patients were enrolled in the randomized trial and had MR imaging at baseline and follow-up beyond 12 weeks from completion of radiotherapy. "Clinical progression"was based on a clinical radiology report of progression and/or change in treatment for progression. Results. Of 90 enrolled patients, 66 were evaluable. Median clinical progression-free survival (PFS) was 10.8 (range: 9.4-14.7) months; 10.8 months IMRT versus 11.2 months PT (P = .14). Median RANO-PFS was 8.2 (range: 6.9, 12): 8.9 months IMRT versus 6.6 months PT (P = .24). RANO-PFS was significantly shorter than clinical PFS overall (P = .001) and for both the IMRT (P = .01) and PT (P = .04) groups. There were 31 (46.3%) discrepant cases of which 17 had RANO progression more than a month prior to clinical progression, and 14 had progression by RANO but not clinical criteria. Conclusions. Based on this secondary analysis of a trial of PT versus IMRT for glioblastoma, while no difference in PFS was noted relative to treatment technique, RANO criteria identified progression more often and earlier than clinical assessment. This highlights the disconnect between measures of tumor response in clinical trials versus clinical practice. With growing efforts to utilize real-world data and personalized treatment with timely adaptation, there is a growing need to improve the consistency of determining tumor progression within clinical trials and clinical practice.

Original languageEnglish (US)
Article numbervdab073
JournalNeuro-Oncology Advances
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2021
Externally publishedYes

Keywords

  • RANO
  • glioblastoma
  • imaging endpoints
  • progression-free survival
  • radiation therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Surgery

Fingerprint

Dive into the research topics of 'Phase II trial of proton therapy versus photon IMRT for GBM: Secondary analysis comparison of progression-free survival between RANO versus clinical assessment'. Together they form a unique fingerprint.

Cite this